Immune response and inflammation in cancer health disparities.

In the next 30 years, Alzheimer’s disease cases are predicted to drastically increase.

This article ties to SDG 3. In this study, time-varying associations of pre-migration and post-migration stressors in refugees' mental health were explored. Understanding these time-varying association could help in designing tailored health promotion services at different resettlement stages and improving the efficiency of resource allocation.

Proteasome function is impaired in Alzheimer's disease (AD). Proteasome activation is followed by a decrease in amyloid-beta (Aβ) load. A reduced amount of Aβ correlates with significantly improved behavior and frailty level. Proteasome activation represents a promising intervention for alleviating AD pathology.

This Article supports SDG 3 by summarising global, regional, and national estimates of the burden of tracheal, bronchus, and lung cancer and larynx cancer and their attributable risks from 1990 to 2019, and highlighting the importance of preventive measures such as smoking control interventions, air quality management programmes focused on major air pollution sources, and widespread access to clean energy.

Women represent ⅔ of the cases of Alzheimer's disease (AD). Current research has focused on differential risks to explain higher rates of AD in women.

Laughter therapy is a universal non-pharmacologic approach to reduce stress and anxiety. Laughter therapy can be used during COVID-19 pandemic as a useful supplementary therapy to reduce the mental health burden.

Using event-related potentials (ERPs) might help identify early neural changes indicative of future cognitive decline, offering an accessible and affordable alternative to other neuroimaging methods

A good study that looked at the mathematical method to evaluate the drug resistant of virus emergence using HIV/AIDS treatment cases.

Imbalances in redox homeostasis can result in oxidative stress, which is implicated in various pathological conditions including the fatal neuromuscular disease Duchenne Muscular Dystrophy (DMD). DMD is a complicated disease, with many druggable targets at the cellular and molecular level including calcium-mediated muscle degeneration; mitochondrial dysfunction; oxidative stress; inflammation; insufficient muscle regeneration and dysregulated protein and organelle maintenance. Previous investigative therapeutics tended to isolate and focus on just one of these targets and, consequently, therapeutic activity has been limited. Nuclear erythroid 2-related factor 2 (Nrf2) is a transcription factor that upregulates many cytoprotective gene products in response to oxidants and other toxic stressors. Unlike other strategies, targeted Nrf2 activation has the potential to simultaneously modulate separate pathological features of DMD to amplify therapeutic benefits. Here, we review the literature providing theoretical context for targeting Nrf2 as a disease modifying treatment against DMD.